Désirée van der Heijde

117.6k total citations · 35 hit papers
897 papers, 61.2k citations indexed

About

Désirée van der Heijde is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Désirée van der Heijde has authored 897 papers receiving a total of 61.2k indexed citations (citations by other indexed papers that have themselves been cited), including 859 papers in Rheumatology, 293 papers in Immunology and 234 papers in Hematology. Recurrent topics in Désirée van der Heijde's work include Rheumatoid Arthritis Research and Therapies (618 papers), Spondyloarthritis Studies and Treatments (588 papers) and Psoriasis: Treatment and Pathogenesis (262 papers). Désirée van der Heijde is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (618 papers), Spondyloarthritis Studies and Treatments (588 papers) and Psoriasis: Treatment and Pathogenesis (262 papers). Désirée van der Heijde collaborates with scholars based in Netherlands, United States and Germany. Désirée van der Heijde's co-authors include Robert Landewé, Jürgen Braun, Joachim Sieper, Maxime Dougados, Philip J. Mease, Xenofon Baraliakos, Paul Emery, Walter P. Maksymowych, Josef S Smolen and Tore K Kvien and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Désirée van der Heijde

863 papers receiving 59.3k citations

Hit Papers

Infliximab and Methotrexate in the Treatment of Rheumatoi... 1990 2026 2002 2014 2000 2004 2009 2004 1990 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
    2000 2.4k citations Désirée van der Heijde et al. profile →
  2. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    2004 1.4k citations Désirée van der Heijde, Joseph Wajdula et al. profile →
  3. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    2009 1.2k citations Joachim Sieper, Xenofon Baraliakos et al. Annals of the Rheumatic Diseases profile →
  4. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    2004 940 citations Désirée van der Heijde, Joan M. Bathon et al. profile →
  5. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.
    1990 855 citations Désirée van der Heijde, M. A. van Leeuwen et al. Annals of the Rheumatic Diseases profile →
  6. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    1997 800 citations Maarten Boers, Désirée van der Heijde et al. profile →
  7. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
    2008 720 citations Robert Landewé, Joachim Sieper et al. Annals of the Rheumatic Diseases profile →
  8. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
    2006 660 citations Désirée van der Heijde, Joachim Sieper et al. profile →
  9. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis
    2003 655 citations Désirée van der Heijde, Jürgen Braun et al. profile →
  10. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
    2005 651 citations Désirée van der Heijde, Joachim Sieper et al. profile →
  11. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 650 citations Philip J. Mease, Christopher T. Ritchlin et al. profile →
  12. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group
    2009 649 citations Désirée van der Heijde, Xenofon Baraliakos et al. Annals of the Rheumatic Diseases profile →
  13. Development of a disease activity score based on judgment in clinical practice by rheumatologists.
    1993 634 citations Désirée van der Heijde et al. profile →
  14. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    2017 621 citations Désirée van der Heijde, Yoshiya Tanaka et al. profile →
  15. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
    2003 583 citations Désirée van der Heijde, Jürgen Braun et al. profile →
  16. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
    2015 572 citations Philip J. Mease, Désirée van der Heijde et al. profile →
  17. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
    2010 549 citations Pedro Machado, Robert Landewé et al. Annals of the Rheumatic Diseases profile →
  18. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
    2014 536 citations Sofía Ramiro, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  19. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial
    2005 500 citations Désirée van der Heijde, Robert Landewé et al. profile →
  20. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
  21. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Désirée van der Heijde, Yoshiya Tanaka et al. profile →
  22. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
    2008 455 citations Désirée van der Heijde, Tore K Kvien et al. Annals of the Rheumatic Diseases profile →
  23. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
    2013 448 citations Mikkel Østergaard, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  24. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
    2008 444 citations Robert D. Inman, Désirée van der Heijde et al. profile →
  25. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  26. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
    2017 421 citations Philip J. Mease, Oliver FitzGerald et al. profile →
  27. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Désirée van der Heijde, Tsutomu Takeuchi et al. profile →
  28. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
    2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  29. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
    2017 272 citations Désirée van der Heijde, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
  30. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    2020 242 citations Philip J. Mease, Désirée van der Heijde et al. profile →
  31. Axial spondyloarthritis
    2021 202 citations Victoria Navarro‐Compán, Alexandre Sepriano et al. Annals of the Rheumatic Diseases profile →
  32. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
    2020 195 citations Alexandre Sepriano, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  33. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Yoshiya Tanaka, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  34. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
    2021 159 citations Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases profile →
  35. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
    2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Désirée van der Heijde Netherlands 122 52.7k 22.4k 19.4k 5.3k 5.0k 897 61.2k
Paul Emery United Kingdom 123 45.9k 0.9× 18.2k 0.8× 17.3k 0.9× 3.3k 0.6× 7.7k 1.5× 1.0k 67.0k
Josef S Smolen Austria 89 25.5k 0.5× 10.1k 0.5× 9.6k 0.5× 795 0.2× 3.9k 0.8× 509 35.4k
Robert Landewé Netherlands 83 20.5k 0.4× 8.8k 0.4× 6.7k 0.3× 2.6k 0.5× 2.0k 0.4× 532 25.0k
Dafna D. Gladman Canada 102 38.1k 0.7× 30.8k 1.4× 13.6k 0.7× 858 0.2× 3.9k 0.8× 959 47.9k
Gene G. Hunder United States 77 30.3k 0.6× 6.7k 0.3× 4.6k 0.2× 1.6k 0.3× 4.3k 0.9× 217 49.4k
Frank C. Arnett United States 67 24.3k 0.5× 9.2k 0.4× 5.6k 0.3× 1.2k 0.2× 7.2k 1.5× 196 37.7k
Maxime Dougados France 83 18.9k 0.4× 6.4k 0.3× 5.4k 0.3× 2.4k 0.5× 2.2k 0.4× 395 24.8k
Ben A. C. Dijkmans Netherlands 83 18.3k 0.3× 6.3k 0.3× 6.1k 0.3× 1.5k 0.3× 2.3k 0.5× 332 25.0k
Yoshiya Tanaka Japan 80 14.5k 0.3× 9.6k 0.4× 5.2k 0.3× 958 0.2× 2.8k 0.6× 1.1k 30.4k
Maxime Dougados France 74 19.5k 0.4× 9.4k 0.4× 6.9k 0.4× 2.2k 0.4× 1.9k 0.4× 546 23.9k

Countries citing papers authored by Désirée van der Heijde

Since Specialization
Citations

This map shows the geographic impact of Désirée van der Heijde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Désirée van der Heijde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Désirée van der Heijde more than expected).

Fields of papers citing papers by Désirée van der Heijde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Désirée van der Heijde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Désirée van der Heijde. The network helps show where Désirée van der Heijde may publish in the future.

Co-authorship network of co-authors of Désirée van der Heijde

This figure shows the co-authorship network connecting the top 25 collaborators of Désirée van der Heijde. A scholar is included among the top collaborators of Désirée van der Heijde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Désirée van der Heijde. Désirée van der Heijde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Heijde, Désirée van der, Victoria Navarro‐Compán, R. Landewé, et al.. (2025). 1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis. Annals of the Rheumatic Diseases. 84(3). 382–387.
3.
Ramiro, Sofía, M. van Lunteren, Robert Landewé, et al.. (2024). Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort. Annals of the Rheumatic Diseases. 83(5). 589–598. 15 indexed citations
4.
Landewé, Robert, et al.. (2023). Robust analyses for radiographic progression in rheumatoid arthritis. RMD Open. 9(2). e002543–e002543.
5.
Benavent, Diego, Désirée van der Heijde, Robert Landewé, et al.. (2022). Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Lara D. Veeken. 62(4). 1398–1409. 19 indexed citations
6.
Deodhar, Atul, Huji Xu, Xenofon Baraliakos, et al.. (2021). Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 80(8). 1004–1013. 159 indexed citations breakdown →
7.
Tanaka, Yoshiya, Satoshi Soen, Naoki Ishiguro, et al.. (2020). Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open. 6(2). e001249–e001249. 7 indexed citations
8.
Sepriano, Alexandre, Sofía Ramiro, Désirée van der Heijde, et al.. (2020). What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Annals of the Rheumatic Diseases. 79(3). 324–331. 45 indexed citations
9.
10.
11.
Siebuhr, Anne Sofie, Désirée van der Heijde, Anne‐Christine Bay‐Jensen, et al.. (2018). Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. RMD Open. 4(1). e000648–e000648. 11 indexed citations
12.
Mihai, Carina, Robert Landewé, Désirée van der Heijde, et al.. (2015). Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases. 75(4). 681–686. 95 indexed citations
13.
Kloppenburg, M., Pernille Bøyesen, Annemieke Visser, et al.. (2015). Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. The Journal of Rheumatology. 42(11). 2190–2197. 62 indexed citations
14.
Maksymowych, Walter P., Maxime Dougados, Désirée van der Heijde, et al.. (2015). Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases. 75(7). 1328–1335. 80 indexed citations
15.
16.
Ramiro, Sofía, Robert Landewé, Annelies Boonen, et al.. (2014). A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis. Data Archiving and Networked Services (DANS). 1 indexed citations
17.
Kloppenburg, M., Pernille Bøyesen, Wilma Smeets, et al.. (2014). Report from the OMERACT Hand Osteoarthritis Special Interest Group: Advances and Future Research Priorities. The Journal of Rheumatology. 41(4). 810–818. 32 indexed citations
18.
Bakker, P., Ronald van den Berg, F. van Gaalen, et al.. (2014). IMPACT OF REPEATING IMAGING OF THE SACROILIAC JOINTS OVER ONE YEAR ON THE CLASSIFICATION ACCORDING THE ASAS AXIAL SPA CRITERIA OF PATIENTS. Clinical and Experimental Rheumatology. 32(5). 787–787. 1 indexed citations
19.
Syversen, Silje Watterdal, Robert Landewé, Désirée van der Heijde, et al.. (2009). Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. The Journal of Rheumatology. 36(8). 1769–1784. 12 indexed citations
20.
Heijde, Désirée van der, Piet L. C. M. van Riel, M. A. van Leeuwen, et al.. (1992). PROGNOSTIC FACTORS FOR RADIOGRAPHIC DAMAGE AND PHYSICAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS. A PROSPECTIVE FOLLOW-UP STUDY OF 147 PATIENTS. Lara D. Veeken. 31(8). 519–525. 231 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Emery Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Robert Landewé Breakdown of academic impact, for papers by Dafna D. Gladman Breakdown of academic impact, for papers by Gene G. Hunder Breakdown of academic impact, for papers by Frank C. Arnett Breakdown of academic impact, for papers by Maxime Dougados Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Yoshiya Tanaka Breakdown of academic impact, for papers by Maxime Dougados
Rankless by CCL
2026